Beck Mack & Oliver LLC Sells 3,325 Shares of Johnson & Johnson $JNJ

Beck Mack & Oliver LLC lessened its stake in Johnson & Johnson (NYSE:JNJ) by 1.4% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 226,955 shares of the company’s stock after selling 3,325 shares during the period. Beck Mack & Oliver LLC’s holdings in Johnson & Johnson were worth $34,667,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of JNJ. Clark Asset Management LLC grew its stake in shares of Johnson & Johnson by 51.6% in the second quarter. Clark Asset Management LLC now owns 8,884 shares of the company’s stock worth $1,357,000 after purchasing an additional 3,025 shares during the last quarter. Apexium Financial LP grew its position in shares of Johnson & Johnson by 10.7% in the 1st quarter. Apexium Financial LP now owns 23,989 shares of the company’s stock worth $3,978,000 after buying an additional 2,310 shares during the last quarter. Avanza Fonder AB raised its holdings in shares of Johnson & Johnson by 2.9% during the second quarter. Avanza Fonder AB now owns 234,647 shares of the company’s stock valued at $35,842,000 after acquiring an additional 6,566 shares in the last quarter. Winnow Wealth LLC bought a new stake in Johnson & Johnson in the second quarter valued at $295,000. Finally, 111 Capital raised its holdings in Johnson & Johnson by 94.0% in the 2nd quarter. 111 Capital now owns 12,474 shares of the company’s stock worth $1,905,000 after purchasing an additional 6,045 shares in the last quarter. Institutional investors own 69.55% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the stock. Cowen reiterated a “buy” rating on shares of Johnson & Johnson in a research report on Tuesday, October 14th. The Goldman Sachs Group increased their target price on Johnson & Johnson from $186.00 to $212.00 and gave the stock a “buy” rating in a research report on Thursday, October 9th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Johnson & Johnson in a research note on Friday, October 31st. Sanford C. Bernstein boosted their target price on shares of Johnson & Johnson from $172.00 to $193.00 and gave the company a “market perform” rating in a report on Monday, October 6th. Finally, Johnson Rice set a $190.00 price target on shares of Johnson & Johnson and gave the company a “hold” rating in a research report on Wednesday, October 22nd. Four research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $206.65.

Johnson & Johnson Trading Up 0.8%

Shares of NYSE JNJ opened at $211.65 on Friday. The company has a market cap of $509.93 billion, a PE ratio of 20.43, a P/E/G ratio of 2.34 and a beta of 0.36. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.80 and a current ratio of 1.07. The firm’s 50 day moving average price is $196.09 and its 200-day moving average price is $177.08. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $212.27.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. The business had revenue of $24.02 billion for the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%. On average, equities research analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th were given a $1.30 dividend. The ex-dividend date of this dividend was Tuesday, November 25th. This represents a $5.20 dividend on an annualized basis and a yield of 2.5%. Johnson & Johnson’s payout ratio is 50.19%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.